Marco Herling (MD)

Department I of Internal Medicine, Center for Integrated Oncology (CIO), Aachen-Bonn-Cologne-Duesseldorf, University of Cologne, Cologne, Germany; Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), Cologne, Germany; Center for Molecular Medicine Cologne (CMMC), Cologne, Germany

Dr. Herling graduated from Martin-Luther-University (MLU) Halle-Wittenberg medical school in 1999. In his doctoral theses work on experimentally induced soft tissue sarcomas from 1994-1999 at the MLU Institute of Pathology, he studied pre-malignant mesenchymal changes and tumor host interactions on the basis of cellular glycoprotein-receptor patterns. With a stipend through the Biomedical Sciences Exchange Program, Dr. Herling worked as a medical student with mentors Drs. A.H. Sarris and L.J. Medeiros on the development of prognostic marker profiles in anaplastic large cell lymphoma and Hodgkin lymphoma between 1997-98 at the Department of Lymphoma and Myeloma at the M. D. Anderson Cancer Center (MDACC), Houston, Texas. In 2000, he entered his clinical training at the Department of Hematology/Oncology at the University of Freiburg chaired by Dr. R. Mertelsmann. He spent his postdoctoral fellowship from 2002-2006 at the MDACC’s Department of Hematopathology in the laboratory of Dr. D. Jones. There, he investigated transforming mechanisms in T-cell malignancies with focus on the role of the oncogene TCL1. Between 2002-05, Dr. Herling was enrolled in the NIH Physician Scientist Training Program headed by Dr. E. J. Freireich completing the curriculum with a proposal and clinical implementation of novel trial approaches in T-PLL. As an awardee of the MDACC Odyssey Fellowship, Dr. Herling extended his research to the signaling pathways relevant in the precursor transformation and tumor progression in CLL.

With a stipend by the DFG, he joined the team around Dr. M. Hallek at the Department of Medicine I at Cologne University in 2007, where he led a Max-Eder junior research group from 2008 -2015 around the description and targeting of kinase interactions induced by environmental survival signals in CLL. He also headed the departmental diagnostic immunophenotyping in 2006 – 2010.

As a specialist in Internal Medicine and Hematology and Oncology, he oversees the scientific and clinical program in mature T-cell leukemias, e.g. T-PLL including a second-opinion office or a nation-wide registry.

Since 2010 Dr. Herling holds a position as Adjunct Assistant Professor at the Department of Hematopathology at the MDACC.

Dr. Herling is a member of the American Society of Hematology, the American Society of Oncology, the American Association for Cancer Research, the German Society of Hematology and Oncology and other societies.

Research Areas

  • The role and regulation of antigen receptor signaling in lymphatic oncogenesis
  • Specific interception in protein kinase interactions in oncogenesis
  • Specific interception in protein kinase interactions in oncogenesis
  • Histogenetic, functional, and target-based classification of lymphatic tumors
  • Optimized therapies for mature T-cell tumors
  • Diagnosis, prognostication and clinical management of mature lymphatic malignancies of T-cell and B-cell lineage
  • Novel approaches to clinical trial designs in translational malignant Hematology Evidence based supportive care

Contact Information

PD Dr. med. Marco Herling
University Hospital of Cologne
Building 74
Weyertal 115c
50931 Cologne, Germany
tel: +49 221 478 51464